Publications
- Thyroid transcription factor 1 and p63 expression is associated with survival outcome in patients with non-small cell lung cancer treated with erlotinib2020 | Faculty of Medicine in Pilsen
- Effect of clinical parameters on second- and third-line erlotinib treatment of EGFR wild type patients with advanced NSCLC2019 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Second Faculty of Medicine, Central Library of Charles University
- Patient with three EGFR mutations - gradual development of resistance to previous targeted treatment2018 | Faculty of Medicine in Pilsen, Faculty of Science
- Diagnosing lung cancer in pulmonology centers2018 | First Faculty of Medicine, Second Faculty of Medicine
- Osimertinib - a new treatment option for patients with EGFR mutation T790M2017 | Faculty of Medicine in Pilsen, First Faculty of Medicine
- Modern treatment of non-small cell lung carcinoma2017 | Faculty of Medicine in Pilsen
- Erlotinib in treatment of NSCLC focusing on patients without EGFR mutation and on combination of erlotinib with bevacizumab2017 | Faculty of Medicine in Pilsen
- Erlotinib in Treatment of NSCLC (Focusing on Patients without EGFR Mutation and on Combination of Erlotinib with Bevacizumab)2017 | Faculty of Medicine in Pilsen
- Epidermal Growth Factor Receptor Gene Amplification in Patients with Advanced-stage NSCLC2016 | Faculty of Medicine in Pilsen, Faculty of Science
- Current status and prospects of targeted therapies non-small cell lung cancer2016 | Faculty of Medicine in Pilsen
Loading network view...